Is Krystal Biotech (KRYS) overvalued or fairly valued?

MarketChacha shows Krystal Biotech's valuation in context — a trailing P/E of about 43.6, a forward P/E of about 34.1, a price-to-book of about 7.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krystal Biotech's revenue?

Krystal Biotech reported revenue of $389.1M for FY2025, with net profit of $204.8M, per official filings.

What is the share price of Krystal Biotech (KRYS)?

Krystal Biotech last traded at $329.91 (+0.5% on the day), as of 8/14/2026 — a delayed quote shown for education, not investment advice.

Krystal Biotech

KRYS · NYSE · Healthcare · United States

Snapshot

TickerKRYS

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees295

HeadquartersPittsburgh, United States

Websitewww.krystalbio.com

Filings tracked17

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Who owns it

Insiders10.9%
Institutions89.1%
Public & other0.0%

564 institutional holders

Ownership breakdown from public market data.

Top holders

FMR, LLC14.78%
Blackrock Inc.14.13%
Avoro Capital Advisors LLC9.76%
Vanguard Portfolio Management LLC4.92%
State Street Corporation4.56%
Vanguard Capital Management LLC3.94%
Soleus Capital Management, L.P.3.17%
Capital World Investors2.63%

Largest institutional holders — last updated 3/31/2026.

Forensic scorecard

Over 3 years only 0.77× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.77×

Net margin trend21.6% → 52.6%

Margin has expanded by about 31.1 points — the business is getting more profitable.

Return on equity16.8%

Latest ROE of 16.8% — capital is generating a healthy return.

Growth qualityrev 177% · PAT 333%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $137.5M · EPS 2.15

Est. earnings growth +26.4%

Next fiscal year

Rev $654.7M · EPS 9.32

Est. earnings growth +19.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$389.1M

Net margin

52.6%

ROE

16.8%

Revenue CAGR (2y)

+177.0%

Profit CAGR (2y)

+332.9%

EPS (FY2025)

6.84

Net profit (FY2025)

$204.8M

Ask MarketChacha about KRYS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$389.1M	$204.8M	6.84	52.6%	16.8%
FY2024	$290.5M	$89.2M	3.00	30.7%	9.4%
FY2023	$50.7M	$10.9M	0.39	21.6%	1.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$119.2M	$54.8M	1.79	45.9%
2026Q1	$116.4M	$55.9M	1.83	48.1%
2025Q3	$97.8M	$79.4M*	2.66	—
2025Q2	$96.0M	$38.3M	1.29	39.9%
2025Q1	$88.2M	$35.7M	1.20	40.5%
2024Q3	$83.8M	$27.2M	0.91	32.4%
2024Q2	$70.3M	$15.6M	0.53	22.2%
2024Q1	$45.3M	$932,000	0.03	2.1%
2023Q3	$8.6M	$80.7M*	2.79	—
2023Q2	$0	$-33.2M	-1.25	—
2023Q1	$0	$-45.3M	-1.76	—

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/3/2026
8-K — Results of operations, Exhibits
SEC8/3/2026material
8-K — Other events, Exhibits
SEC7/21/2026material
8-K — Shareholder vote results
SEC5/20/2026material
10-Q filing
SEC5/4/2026
8-K — Exhibits
SEC5/4/2026material
10-K filing
SEC2/17/2026
8-K — Results of operations
SEC2/17/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC1/12/2026material
8-K — Reg FD disclosure, Exhibits
SEC1/8/2026material

2025

8-K — Executive/director change, Exhibits
SEC12/23/2025material
10-Q filing
SEC11/3/2025
8-K — Results of operations
SEC11/3/2025material
8-K — Other events
SEC10/22/2025material
10-Q filing
SEC8/4/2025
8-K — Results of operations, Exhibits
SEC8/4/2025material
8-K — Reg FD disclosure
SEC7/25/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.